Halaven eribulin mesylate 1mg for sale

Halaven eribulin mesylate 1mg for sale 

Specifications for Halaven eribulin mesylate 1mg

Halaven (eribulin)

     Brand name----------------Halaven

     Generic name--------------eribulin

     Dosage form---------------Injection

     Dosage--------------------1mg/2ml

     Drug class----------------mitotic inhibitors

     Company-------------------Eisai Co

Halaven (eribulin) drug information

       NDC code----------------------62856-389-01

       LOT NO------------------------117405

       Expiry Date-------------------03 / 2020

Halaven (eribulin) Usage

      * Interferes with the growth and spread of cancer cells in the body           

      * Used to treat breast cancer that has spread to other parts of the body

      * Used to treat soft tissue sarcoma called liposarcoma that cannot be removed by surgery             

       

Halaven (eribulin) Price           

      Price-------------------$950 .00 USD (Per unit $950.00 USD)

      Quantity----------------1 vials

      Dosage------------------1mg/2ml

Breast cancer:

Indications for HALAVEN:

Treatment of metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Adult:

Give by IV inj over 2–5mins. 1.4mg/m² on Days 1 and 8 of a 21-day cycle. Mild hepatic impairment (Child-Pugh A) or moderate-to-severe renal impairment (CrCl 15–49mL/min): 1.1mg/m² on Days 1 and 8 of a 21-day cycle. Moderate hepatic impairment (Child-Pugh B): 0.7mg/m² on Days 1 and 8 of a 21-day cycle. Hold dose for ANC <1000 3="" 4="" according="" after="" delay="" do="" dose="" full="" grade="" is="" it="" labeling.="" mm="" non-hematological="" not="" or="" p="" platelets="" re-escalate="" reduce="" reduced.="" see="" to="" toxicities.="" toxicities="">

Children:

<18yrs: established.="" not="" p="">

Warnings/Precautions:

Monitor CBCs prior to each dose; increase frequency of monitoring if grade 3 or 4 cytopenias develop, delay and reduce subsequent doses if febrile neutropenia or grade 4 neutropenia lasting >7 days develops. Monitor for peripheral neuropathy; withhold dose if grade 3 or 4 peripheral neuropathy develops until resolution to grade 2 or less. Congenital long QT syndrome: avoid. CHF, bradyarrhythmias, electrolyte abnormalities: monitor ECG for prolonged QT interval. Correct electrolyte abnormalities (K+, Mg+) before treatment; monitor. Severe hepatic impairment (Child-Pugh C): insufficient data. Embryo-fetal toxicity. Pregnancy (avoid). Use effective contraception during treatment and for ≥2 weeks (females) or 3.5 months (male partners) after final dose. Nursing mothers: not recommended (during and for 2 weeks after final dose).

Pharmacologic Class:

Non-taxane microtubule dynamics inhibitor.

Interactions:

Caution with other drugs that prolong QT interval (eg, Class IA and III antiarrhythmics); monitor.

Adverse Reactions:

Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation, abdominal pain, pyrexia, hypokalemia, hypocalcemia; febrile neutropenia, possible QT prolongation, elevated liver enzymes.

Note:

Do not mix with dextrose-containing solutions. Do not administer in same line as other drugs or fluids.

How Supplied:

Single-use vial (2mL)—1 

Click here for more details

Halaven - Buy and Check Prices Online for Halaven

Halaven (eribulin mesylate)

HALAVEN® (eribulin mesylate) Injection

halaven 2mg price in india

eribulin mesylate manufacturer in india

halaven injection price

halaven injection price in india

halaven cost

eribulin mesylate brands in india

eribulin interactions

eribulin emcure